Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04165941 · ClinicalTrials.gov registry record · Phase 1
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma
A Phase 1 study of Brain Tumor Adult, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04165941: Active Phase 1 study of Brain Tumor Adult, sponsored by University of Alabama at Birmingham.
NCT04165941 is a Phase 1 study of Brain Tumor Adult that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 22 participants, below the 76-participant average among 6 other Brain Tumor Adult trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04165941, a Phase 1 study of Brain Tumor Adult, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to find out if the safety and tolerability of an experimental cell therapy is safe to administer to patients with a newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide (TMZ).
Primary Outcome
Safety and toxicity of intracranially infused DRI gamma delta T cells
Conditions Studied
Interventions
- BIOLOGICAL DRI cell therapy
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-02-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT04165941 still lists
NCT04165941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 76-participant average among 6 other Brain Tumor Adult trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Brain Tumor Adult appearing as the primary indexed condition, and to 1 intervention - of which DRI cell therapy is the first listed.
NCT04165941 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04165941 about?
NCT04165941 is a clinical study titled "Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma". This study is being conducted to find out if the safety and tolerability of an experimental cell therapy is safe to administer to patients with a newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide (TMZ).
What is the current status of trial NCT04165941?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-02-11. Estimated completion is 2026-12-31.
What conditions does trial NCT04165941 study?
This clinical trial studies the following conditions: Brain Tumor Adult.
What interventions are being tested in trial NCT04165941?
The interventions under investigation include: DRI cell therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04165941?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04165941 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
-
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
RECRUITING
-
Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures
RECRUITING · Phase 4
-
A Study of Cognitive Changes in Patients Receiving Brain Radiation
ACTIVE NOT RECRUITING
-
Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI